17:12 EDT Enlivex Therapeutics (ENLV) files $300M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex’s Promising Clinical Progress and Strategic Collaborations Justify Buy Rating
- Enlivex to Present Allocetra™ Insights at OARSI 2025
- Enlivex Completes Phase II Enrollment for Osteoarthritis Trial
- Enlivex completed enrollment of patients in Phase II trial of Allocetra
- Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment